Journal Sentinel, December 29, 2011

Even before it went on the market in 2002, doctors were talking about how the back surgery product known as bone morphogenetic protein-2 would revolutionize medicine. It did - but in ways no one imagined. Instead of offering 100% success in fusing ailing spines with virtually no complications, BMP-2 became a biotech breakthrough associated with skepticism and scandal, epitomizing questions over whether corporate-funded research carried out by financially conflicted doctors can be trusted.
Facebook icon
LinkedIn icon
Twitter icon